Koers RXi Pharmaceuticals Corp Nasdaq
Aandelen
US74979C3034
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,37 mln. 3,11 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -9 mln. -8,31 mln. | Nettowinst (verlies) 2025 * | 47 mln. 43,41 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,4
x | K/w-verhouding 2025 * |
0,19
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Director/Board Member | 73 | 02-05-22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18-04-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,03% | 49,18 mld. | |
-0,10% | 42,11 mld. | |
+46,62% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+11,48% | 26,09 mld. | |
-22,74% | 18,71 mld. | |
+9,06% | 13,26 mld. | |
+30,01% | 12,32 mld. | |
-1,51% | 11,99 mld. |
- Beurs
- Aandelen
- Koers PHIO
- Koers